Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 54 articles:
HTML format
Text format



Single Articles


    July 2017
  1. DERKS MGM, Blok EJ, Seynaeve C, Nortier JWR, et al
    Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 Jul 18. pii: S1470-2045(17)30419.
    PubMed     Text format     Abstract available


  2. MATHEW A, Brufsky A
    TACT2: improving treatment tolerability in early breast cancer.
    Lancet Oncol. 2017;18:843-845.
    PubMed     Text format    


    June 2017
  3. DAS M
    Adjuvant pertuzumab improves early breast cancer outcomes.
    Lancet Oncol. 2017 Jun 15. pii: S1470-2045(17)30481.
    PubMed     Text format    


  4. DAS M
    Olaparib provides benefit in metastatic breast cancer.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30453.
    PubMed     Text format    


  5. BURKI TK
    Adjuvant capecitabine for HER2-negative breast cancer.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30451.
    PubMed     Text format    


  6. CAMERON D, Morden JP, Canney P, Velikova G, et al
    Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, co
    Lancet Oncol. 2017 Jun 6. pii: S1470-2045(17)30404.
    PubMed     Text format     Abstract available


  7. STEBBING J, Baranau Y, Baryash V, Manikhas A, et al
    CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
    Lancet Oncol. 2017 Jun 2. pii: S1470-2045(17)30434.
    PubMed     Text format     Abstract available


    May 2017
  8. CHOPRA N, Turner NC
    Targeting PIK3CA-mutant advanced breast cancer in the clinical setting.
    Lancet Oncol. 2017 May 30. pii: S1470-2045(17)30430.
    PubMed     Text format    


  9. BASELGA J, Im SA, Iwata H, Cortes J, et al
    Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 May 30. pii: S1470-2045(17)30376.
    PubMed     Text format     Abstract available


  10. KROP IE, Kim SB, Martin AG, LoRusso PM, et al
    Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30313.
    PubMed     Text format     Abstract available


  11. MONTEMURRO F
    Trastuzumab emtansine in HER2-positive metastatic breast cancer.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30303.
    PubMed     Text format    


  12. DIERAS V, Miles D, Verma S, Pegram M, et al
    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30312.
    PubMed     Text format     Abstract available


  13. ALLGOOD PC, Maroni R, Hudson S, Offman J, et al
    Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.
    Lancet Oncol. 2017 May 15. pii: S1470-2045(17)30340.
    PubMed     Text format     Abstract available


  14. GOURD E
    Switch to exemestane effective in early breast cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30341.
    PubMed     Text format    


  15. EARL HM, Hiller L, Howard HC, Dunn JA, et al
    Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 May 4. pii: S1470-2045(17)30319.
    PubMed     Text format     Abstract available


    April 2017
  16. FOUAD TM, Barrera AM, Reuben JM, Lucci A, et al
    Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.
    Lancet Oncol. 2017;18:e228-e232.
    PubMed     Text format     Abstract available


    March 2017
  17. BURKI TK
    Sacituzumab govitecan activity in advanced breast cancer.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30232.
    PubMed     Text format    


  18. RUGO HS, Seneviratne L, Beck JT, Glaspy JA, et al
    Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
    Lancet Oncol. 2017 Mar 14. pii: S1470-2045(17)30109.
    PubMed     Text format     Abstract available


    February 2017
  19. MAYOR S
    Service review: improving breast cancer care in Tanzania.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30160.
    PubMed     Text format    


  20. MATHEW A, Brufsky A
    Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30150.
    PubMed     Text format    


  21. BROWER V
    Scalp cooling and hair loss during breast cancer chemotherapy.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30158.
    PubMed     Text format    


  22. LLOMBART-CUSSAC A, Cortes J, Pare L, Galvan P, et al
    HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30021.
    PubMed     Text format     Abstract available


  23. ZHANG P, Sun T, Zhang Q, Yuan Z, et al
    Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Lancet Oncol. 2017 Feb 10. pii: S1470-2045(17)30088.
    PubMed     Text format     Abstract available


  24. BROWER V
    Letrozole not superior to anastrozole for early breast cancer.
    Lancet Oncol. 2017 Feb 2. pii: S1470-2045(17)30081.
    PubMed     Text format    


  25. POLGAR C, Ott OJ, Hildebrandt G, Kauer-Dorner D, et al
    Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year r
    Lancet Oncol. 2017;18:259-268.
    PubMed     Text format     Abstract available


  26. DIKMANS RE, Negenborn VL, Bouman MB, Winters HA, et al
    Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial.
    Lancet Oncol. 2017;18:251-258.
    PubMed     Text format     Abstract available


    January 2017
  27. LUEN SJ, Salgado R, Fox S, Savas P, et al
    Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Lancet Oncol. 2017;18:52-62.
    PubMed     Text format     Abstract available


    December 2016
  28. TANDAY S
    Duloxetine lessens joint pain in early-stage breast cancer.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30656.
    PubMed     Text format    


  29. GOURD K
    San Antonio Breast Cancer Symposium 2016.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30658.
    PubMed     Text format    


  30. BURKI TK
    Incidence of breast cancer in women with type 2 diabetes.
    Lancet Oncol. 2016;17:e523.
    PubMed     Text format    


    November 2016
  31. BURKI TK
    Palbociclib improves survival in advanced breast cancer.
    Lancet Oncol. 2016 Nov 24. pii: S1470-2045(16)30619.
    PubMed     Text format    


  32. VENKATESAN P
    Trastuzumab emtansine for HER2-positive breast cancer.
    Lancet Oncol. 2016 Nov 17. pii: S1470-2045(16)30589.
    PubMed     Text format    


    October 2016
  33. BURKI TK
    Ribociclib in HR-positive, HER2-negative breast cancer.
    Lancet Oncol. 2016 Oct 13. pii: S1470-2045(16)30502.
    PubMed     Text format    


  34. JATOI I, Benson JR, Toi M
    De-escalation of axillary surgery in early breast cancer.
    Lancet Oncol. 2016;17:e430-e441.
    PubMed     Text format     Abstract available


    September 2016
  35. ASDOURIAN MS, Skolny MN, Brunelle C, Seward CE, et al
    Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis.
    Lancet Oncol. 2016;17:e392-405.
    PubMed     Text format     Abstract available


    August 2016
  36. BALAKRISHNAN VS
    Physical exercise might affect breast cancer outcomes.
    Lancet Oncol. 2016 Aug 11. pii: S1470-2045(16)30389.
    PubMed     Text format    


  37. BRUFSKY A
    Is there room for bevacizumab in metastatic breast cancer?
    Lancet Oncol. 2016 Aug 5. pii: S1470-2045(16)30295.
    PubMed     Text format    


  38. ZIELINSKI C, Lang I, Inbar M, Kahan Z, et al
    Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Lancet Oncol. 2016 Aug 5. pii: S1470-2045(16)30154.
    PubMed     Text format     Abstract available


    July 2016
  39. TANDAY S
    IVF treatment not linked to breast cancer.
    Lancet Oncol. 2016 Jul 21. pii: S1470-2045(16)30371.
    PubMed     Text format    


  40. BAKER H
    Adaptive treatments show promise in breast cancer.
    Lancet Oncol. 2016 Jul 14. pii: S1470-2045(16)30315.
    PubMed     Text format    


  41. GHISLAIN I, Zikos E, Coens C, Quinten C, et al
    Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.
    Lancet Oncol. 2016;17:e294-304.
    PubMed     Text format     Abstract available


    June 2016
  42. BERNARDI D, Macaskill P, Pellegrini M, Valentini M, et al
    Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.
    Lancet Oncol. 2016 Jun 23. pii: S1470-2045(16)30101.
    PubMed     Text format     Abstract available


  43. VAN MAAREN MC, de Munck L, de Bock GH, Jobsen JJ, et al
    10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.
    Lancet Oncol. 2016 Jun 22. pii: S1470-2045(16)30067.
    PubMed     Text format     Abstract available


  44. BERTUCCI F, Viens P, Birnbaum D
    SPAG5: the ultimate marker of proliferation in early breast cancer?
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30092.
    PubMed     Text format    


  45. ABDEL-FATAH TM, Agarwal D, Liu DX, Russell R, et al
    SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)00174.
    PubMed     Text format     Abstract available


    May 2016
  46. GIANNI L, Pienkowski T, Im YH, Tseng LM, et al
    5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Lancet Oncol. 2016 May 11. pii: S1470-2045(16)00163.
    PubMed     Text format     Abstract available


  47. BACHELOT T, Campone M, Tredan O
    PI3K targeting in breast cancer: the end of the beginning?
    Lancet Oncol. 2016 May 4. pii: S1470-2045(16)00148.
    PubMed     Text format    


  48. KROP IE, Mayer IA, Ganju V, Dickler M, et al
    Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2016 May 4. pii: S1470-2045(16)00106.
    PubMed     Text format     Abstract available


  49. CHAN A, Buyse M, Yao B
    Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.
    Lancet Oncol. 2016;17:e176-7.
    PubMed     Text format    


  50. HASEGAWA T, Uno H, Wei LJ
    Neratinib after trastuzumab in patients with HER2-positive breast cancer.
    Lancet Oncol. 2016;17:e176.
    PubMed     Text format    


    February 2016
  51. BURKI TK
    Happygram.
    Lancet Oncol. 2016;17:152.
    PubMed     Text format    


  52. BAKER H
    Familial risk in patients with carcinoma of unknown primary.
    Lancet Oncol. 2016;17:e48.
    PubMed     Text format    


    January 2016
  53. EVANS A
    Detection of DCIS and reduced invasive interval cancers.
    Lancet Oncol. 2016;17:14-5.
    PubMed     Text format    


  54. BALAKRISHNAN VS
    Patient risk factors versus physician guidelines for anti-emetics.
    Lancet Oncol. 2016;17:e7.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: